top of page
tech background.png

About us

Mark Summers set out on his journey to solve the problem of slow clinical trial enrollment by founding ThreeWire. As trailblazers in the field of patient recruitment, the investment community initially had its doubts, and while most said no, the company moved forward with the support of a few close investors. Over time, Natan Paz joined to expand the company internationally, beating the odds (and those initial doubts) and in the end, fundamentally changing the clinical trial market, becoming an industry leader, operating in over 40 countries worldwide and creating billions of dollars in value. Today, the field of patient recruitment attracts mainstream investments and acquisitions.

It all started in 1999…

While one problem was being solved, Mark and Natan recognized another issue. Patients came home after treatments in the hospitals and had to deal with debilitating side effects, questions about dosing, and difficulty reaching their care teams. At the same time, care teams were becoming overwhelmed by patient load and having to manage processes from afar. It was clear that the process of at-home cancer medication treatment was broken.

With experience trailblazing new fields and supported by the same investors, Dosentrx and ReX were born. Alan Paz joined the team as founder and CTO to build the platform. Similar to ThreeWire, Dosentrx works together with data, service technology, pharmaceutical companies, doctors, and pharmacists to ensure that home treatment is effective.

The Dosentrx team


Alan Paz


An inventor entrepreneur who holds over 20 patents, Alan invented, designed, and developed the ReX platform. Alan also developed a medical device business which was sold to Baxter.

“My passion is to mobilize the disciplines of physics, mechanics, plastics, electronics, and software to create complex devices that are easy to use, easy to manufacture, and inexpensive to produce.”

Natan Paz.jpg

Natan Paz

CEO and co-founder

Natan cofounded the European subsidiary of ThreeWire, scaling the business to over 40 countries. Following the acquisition of ThreeWire served as General Manager of the Europe region for WCG, a global leader in clinical trial services.

“Managing dozens of clinical trials, I noticed we over-burden patients... make decisions based on unreliable data. I am proud to lead Dosentrx today in the mission to improve patient experience and safety.”


Kristopher Fuhr

VP Business Dev.

Kris has held roles of increasing responsibility including management and corporate strategy in the pharmaceutical industry at Shionogi, the medical device industry at Hologic, and in the life science industry at WCG.

“Dosentrx is the epitome of helping people. Most uniquely, we help the industry deliver upon their commercial objectives while simultaneously decreasing costs for health insurers.”


Kfir Meidav


Kfir has vast experience designing, implementing, and debugging RT Embedded systems for the communications, UAV, and medical industries. Kfir has led multiple multidisciplinary startup R&D teams to successful IPOs.

“It’s fascinating and exciting to have the opportunity to work on a product such as ReX, a true game-changer in the at-home cancer treatment space.”


Mark Summers


Veteran entrepreneur and founder of ThreeWire, a pharmaceutical services company he grew to 500 employees and sold to a leading global clinical research services firm. Previously a senior executive at Spine-Tech and Alcon.

“Having served on Dosentrx’s Board since 2016 I knew the company had all of the elements for success… Therefore, when the Board asked if I would take on the Executive Chairman role, I couldn’t say no.”


Prof. Chen Shapira

MD, Medical Director

A cardiologist by training, Chen’s passion for practicing medicine to improve peoples’ lives led her to roles including CEO of a hospital and an HMO. Chen also served on the boards of the Israeli Hospital Directors Society and the Auditing Committee of the Israel Medical Association.

“It’s a dream come true to know in real-time how your patient is reacting to the treatment that you prescribed, to be able to intervene quickly and to know that he really took his medication.”

TEAM generic woman.jpg

Kety Bardugo

Director of Operations

With over 18 years of experience in the medical device industry, where she scaled companies from R&D to mass production, making sure that ReX always meets the highest standards.

“The skills I've accumulated during my career come together with this position. This was a real opportunity for me to grow and take the next step in my career.”


Yael Berman

Sr. Product Manager

Yael's background in UX/UI design brings to the team extensive knowledge in product development, research, strategy, and user-centric design. Yael excels in seamlessly connecting the domains of research, design, and technology to craft meaningful and delightful user experiences.

“Being part of ReX enables me to combine my passion for product design with the satisfaction of contributing to a game-changing product. It's an exhilarating and challenging experience.”

External board members

TEAM generic man.jpg

Dan Beck

Dan is the co-founder and co-owner of DPI, a global trading company for milk products. Dan has a key role in the success of both ThreeWire and Dosentrx, he brings business acumen, entrepreneurship, and risk management experience to the board.

TEAM generic man.jpg

Jerry Lieberman

Having held executive positions in some of the world’s leading financial institutions including Citibank, Fidelity, and as President and COO of AllianceBernstein, Jerry adds Human resources, financial, risk management, and executive experience in the financial and pharmaceutical industries to our board. Jerry also serves on the board of Forest Laboratories (through its $25B acquisition by Actavis) and Teva Pharmaceuticals.

TEAM generic man.jpg

Frank Sheehy

Frank has held executive positions as SVP, GM of Medco and SVP, GM of Aetna Health, and President of Accredo (at the time the world’s largest specialty pharmacy). Frank brings executive strategic insights as well as a deep understanding of payers and specialty pharmacy to the board. 

bottom of page